The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia

Blood

Volumn 115, Issue 9, 2010, Pages 1797-1803

  Lubenow, Norbert ^a   Hinz, Peter ^b   Thomaschewski, Simone ^a   Lietz, Theresia ^a   Vogler, Michael ^b   Ladwig, Andrea ^b   Jünger, Michael ^b   Nauck, Matthias ^b   Schellong, Sebastian ^c   Wander, Kathrin ^b   Engel, Georg ^b   Ekkernkamp, Axel ^b   Greinacher, Andreas ^a  

^a UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

^c ACADEMIC TEACHING HOSPITAL DRESDEN FRIEDRICHSTADT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CERTOPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MONOEMBOLEX; THROMBOCYTE FACTOR 4; ANTICOAGULANT AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; HUMAN; HUMERUS FRACTURE; IMMUNE RESPONSE; INCIDENCE; INJURY; MAJOR SURGERY; MINOR SURGERY; ORTHOPEDIC SURGERY; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RISK; SEROCONVERSION; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; ADOLESCENT; AGED; CHEMICALLY INDUCED DISORDER; FEMALE; IMMUNOLOGY; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATION; RISK FACTOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; DOUBLE-BLIND METHOD; FEMALE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; PLATELET FACTOR 4; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; THROMBOCYTOPENIA; THROMBOSIS; WOUNDS AND INJURIES; YOUNG ADULT;

EID: 77950356215     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-07-231506     Document Type: Article

References (26)

1. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 suppl):381S-453S.
2. Arepally GM, Ortel TL. Clinical practice: heparin-induced thrombocytopenia. N Engl J Med. 2006; 355(8):809-817.
3. Newman PM, Chong BH. Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation. Blood. 2000;96(1):182-187.
4. Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of two prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood. 2000;96(3):846-851. (Pubitemid 30616845)
5. Warkentin TE, Elavathil LJ, Hayward CPM, Johnston MA, Russett JI, Kelton JG. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med. 1997;127(9):804-812.
6. Chong BH, Murray B, Berndt MC, Dunlop LC, Brighton T, Chesterman CN. Plasma P-selectin is increased in thrombotic consumptive platelet disorders. Blood. 1994;83(6):1535-1541. (Pubitemid 24081566)
7. Leyvraz PF, Bachmann F, Hoek J, et al. Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin. BMJ. 1991;303(6802):543-548.
8. Ganzer D, Gutezeit A, Mayer G, Greinacher A, Eichler P. Prevention of thromboembolism as a cause of thromboembolic complications. A study of the incidence of heparin-induced thrombocytopenia type II [in German]. Z Orthop Ihre Grenzgeb. 1997;135(6):543-549. (Pubitemid 28063069)
9. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332(20):1330-1335.
10. Warkentin TE, Roberts RS, Hirsh J, Kelton JG. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med. 2003;163(20):2518-2524. (Pubitemid 37385796)
11. Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood. 2005;106(8): 2710-2715. (Pubitemid 41510744)
12. Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 suppl):340S-380S.
13. Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006;4(4):759-765.
14. Gennarelli TA, Wodzin E, eds. The Abbreviated Injury Scale 2005. Barrington, IL: American Association for Automotive Medicine (AAAM); 2006.
15. Eichler P, Budde U, Haas S, et al. First workshop for detection of heparin-induced antibodies: validation of the heparin-induced platelet-activation test (HIPA) in comparison with a PF4/heparin ELISA. Thromb Haemost. 1999;81(4):625-629. (Pubitemid 29178953)
16. Juhl D, Eichler P, Lubenow N, Strobel U, Wessel A, Greinacher A. Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia. Eur J Haematol. 2006;76(5):420-426.
17. Greinacher A, Alban S, Omer-Adam MA, Weitschies Warkentin TE. Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings. Thromb Res. 2008;122(2):211-220.
18. Warkentin TE, Sheppard JA, Sigouin CS, Kohlmann T, Eichler P, Greinacher A. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood. 2006;108(9): 2937-2941.
19. Reilly MP, Taylor SM, Hartman NK, et al. Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcgammaRIIA. Blood. 2001;98(8):2442-2447.
20. Suvarna S, Qi R, Arepally GM. Optimization of a murine immunization model for study of PF4/heparin antibodies. J Thromb Haemost. 2009;7(5): 857-864.
21. Greinacher A, Kohlmann T, Strobel U, Sheppard JI, Warkentin TE. The temporal profile of the anti-PF4/heparin immune response. Blood. 2009; 113(20):4970-4976.
22. Warkentin TE, Sheppard JA, Moore JC, Cook RJ, Kelton JG. Studies of the immune response in heparin-induced thrombocytopenia. Blood. 2009; 113(20):4963-4969.
23. Yamamoto K, Niiya K, Shigematu T, et al. Transient factor VIII inhibitor in a hemophilia patient after staphylococcal septic shock syndrome. Int J Hematol. 2000;72(4):517-519.
24. Kreuter M, Retzlaff S, Enser-Weis U, Berdel WE, Mesters RM. Acquired haemophilia in a patient with gram-negative urosepsis and bladder cancer. Haemophilia. 2005;11(2):181-185. (Pubitemid 40468069)
25. Keeling D, Davidson S, Watson H. Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology. The management of heparin-induced thrombocytopenia. Br J Haematol. 2006;133(3):259-269.
26. Geerts WH, Jay RM, Code KI, et al. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med. 1996;335(10):701-707. (Pubitemid 26287356)